We are analyzing https://link.springer.com/article/10.1007/s004320050110.

Title:
A retrospective and prospective overview of prostate-specific antigen | Journal of Cancer Research and Clinical Oncology
Description:
Since the identification of prostate-specific antigen (PSA), continued technological advances have provided highly sensitive assays for its quantification. Given its lack of disease specificity, and its recent detection at low levels in an increasing number of non-prostatic tissues, PSA is far from being the perfect “tumour” marker (biological marker). However, the positive predictive value of PSA for assessing cancer risk makes PSA the most useful “tumour” marker for monitoring progression and response to treatment among patients with prostate cancer. Earlier detection through screening for elevated levels of PSA, while controversial, has been proposed as a way to decrease prostate cancer mortality. Haematogenous identification of PSA mRNA may provide stage-related prognostic information, and the use of ultrasensitive assays for PSA may permit earlier identification of residual or recurrent cancer, following treatment and the initiation of adjuvant therapy. Various PSA-related concepts, including the ratio of “free” PSA and complexes of PSA with the protease inhibitor, α1-antichymotrypsin, to total PSA, have been proposed and placed within diagnostic and management algorithms. Elevations of PSA in other irregularities of the prostate, notably in benign prostatic hyperplasia, and the increasing frequency and number of non-prostatic tissues, including those in women, expressing PSA, have implications for future immunoassays for PSA and strategies for immunotherapy using PSA-based monoclonal antibodies or vaccines, as well as for the molecular basis for its anomalous expression and physiological function(s).
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Science
Telecommunications

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure how the site profits.

Not all websites focus on profit; some are designed to educate, connect people, or share useful tools. People create websites for numerous reasons. And this could be one such example. Link.springer.com could be secretly minting cash, but we can't detect the process.

Keywords {🔍}

psa, cancer, article, prostate, prostatespecific, antigen, privacy, cookies, content, information, journal, research, publish, search, access, data, including, log, ablin, identification, assays, detection, tumour, marker, discover, markers, springer, optional, personal, parties, policy, find, track, clinical, oncology, retrospective, prospective, overview, cite, richard, explore, levels, increasing, number, nonprostatic, tissues, predictive, treatment, earlier, screening,

Topics {✒️}

benign prostatic hyperplasia prostate-specific antigen month download article/chapter psa-based monoclonal antibodies perfect “tumour” marker privacy choices/manage cookies prostate cancer positive predictive full article pdf psa-related concepts cancer research european economic area clinical oncology aims continued technological advances upper saddle river conditions privacy policy �tumour” marker related subjects accepting optional cookies ultrasensitive assays journal finder publish permit earlier identification diagnostic article ablin recurrent cancer prostatic tissues article journal check access instant access prostate article log privacy policy personal data books a optional cookies information manage preferences article cite journal publish subscription content similar content data protection essential cookies cookies skip institution subscribe biological marker psa mrna �free” psa total psa expressing psa

Schema {🗺️}

WebPage:
      mainEntity:
         headline:A retrospective and prospective overview of prostate-specific antigen
         description: Since the identification of prostate-specific antigen (PSA), continued technological advances have provided highly sensitive assays for its quantification. Given its lack of disease specificity, and its recent detection at low levels in an increasing number of non-prostatic tissues, PSA is far from being the perfect “tumour” marker (biological marker). However, the positive predictive value of PSA for assessing cancer risk makes PSA the most useful “tumour” marker for monitoring progression and response to treatment among patients with prostate cancer. Earlier detection through screening for elevated levels of PSA, while controversial, has been proposed as a way to decrease prostate cancer mortality. Haematogenous identification of PSA mRNA may provide stage-related prognostic information, and the use of ultrasensitive assays for PSA may permit earlier identification of residual or recurrent cancer, following treatment and the initiation of adjuvant therapy. Various PSA-related concepts, including the ratio of “free” PSA and complexes of PSA with the protease inhibitor, α1-antichymotrypsin, to total PSA, have been proposed and placed within diagnostic and management algorithms. Elevations of PSA in other irregularities of the prostate, notably in benign prostatic hyperplasia, and the increasing frequency and number of non-prostatic tissues, including those in women, expressing PSA, have implications for future immunoassays for PSA and strategies for immunotherapy using PSA-based monoclonal antibodies or vaccines, as well as for the molecular basis for its anomalous expression and physiological function(s).
         datePublished:
         dateModified:
         pageStart:583
         pageEnd:594
         sameAs:https://doi.org/10.1007/s004320050110
         keywords:
            Key words Benign prostatic hyperplasia
            Prostate cancer
            Prostate-specific antigen (PSA)
            PSA-related concepts (indices) Ultrasensitive PSA assays
            PSA functions
            Oncology
            Cancer Research
            Internal Medicine
            Hematology
         image:
         isPartOf:
            name:Journal of Cancer Research and Clinical Oncology
            issn:
               1432-1335
               0171-5216
            volumeNumber:123
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Richard J. Ablin
               affiliation:
                     name:Innapharma Inc., 10 Mountainview Road, Suite 301, Upper Saddle River, NJ 07458-1935, USA Tel.: +1(201) 818 1160 Fax: +1(201) 818 3388
                     address:
                        name:Innapharma Inc., 10 Mountainview Road, Suite 301, Upper Saddle River, NJ 07458-1935, USA Tel.: +1(201) 818 1160 Fax: +1(201) 818 3388, , US
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:A retrospective and prospective overview of prostate-specific antigen
      description: Since the identification of prostate-specific antigen (PSA), continued technological advances have provided highly sensitive assays for its quantification. Given its lack of disease specificity, and its recent detection at low levels in an increasing number of non-prostatic tissues, PSA is far from being the perfect “tumour” marker (biological marker). However, the positive predictive value of PSA for assessing cancer risk makes PSA the most useful “tumour” marker for monitoring progression and response to treatment among patients with prostate cancer. Earlier detection through screening for elevated levels of PSA, while controversial, has been proposed as a way to decrease prostate cancer mortality. Haematogenous identification of PSA mRNA may provide stage-related prognostic information, and the use of ultrasensitive assays for PSA may permit earlier identification of residual or recurrent cancer, following treatment and the initiation of adjuvant therapy. Various PSA-related concepts, including the ratio of “free” PSA and complexes of PSA with the protease inhibitor, α1-antichymotrypsin, to total PSA, have been proposed and placed within diagnostic and management algorithms. Elevations of PSA in other irregularities of the prostate, notably in benign prostatic hyperplasia, and the increasing frequency and number of non-prostatic tissues, including those in women, expressing PSA, have implications for future immunoassays for PSA and strategies for immunotherapy using PSA-based monoclonal antibodies or vaccines, as well as for the molecular basis for its anomalous expression and physiological function(s).
      datePublished:
      dateModified:
      pageStart:583
      pageEnd:594
      sameAs:https://doi.org/10.1007/s004320050110
      keywords:
         Key words Benign prostatic hyperplasia
         Prostate cancer
         Prostate-specific antigen (PSA)
         PSA-related concepts (indices) Ultrasensitive PSA assays
         PSA functions
         Oncology
         Cancer Research
         Internal Medicine
         Hematology
      image:
      isPartOf:
         name:Journal of Cancer Research and Clinical Oncology
         issn:
            1432-1335
            0171-5216
         volumeNumber:123
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Richard J. Ablin
            affiliation:
                  name:Innapharma Inc., 10 Mountainview Road, Suite 301, Upper Saddle River, NJ 07458-1935, USA Tel.: +1(201) 818 1160 Fax: +1(201) 818 3388
                  address:
                     name:Innapharma Inc., 10 Mountainview Road, Suite 301, Upper Saddle River, NJ 07458-1935, USA Tel.: +1(201) 818 1160 Fax: +1(201) 818 3388, , US
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Journal of Cancer Research and Clinical Oncology
      issn:
         1432-1335
         0171-5216
      volumeNumber:123
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Innapharma Inc., 10 Mountainview Road, Suite 301, Upper Saddle River, NJ 07458-1935, USA Tel.: +1(201) 818 1160 Fax: +1(201) 818 3388
      address:
         name:Innapharma Inc., 10 Mountainview Road, Suite 301, Upper Saddle River, NJ 07458-1935, USA Tel.: +1(201) 818 1160 Fax: +1(201) 818 3388, , US
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Richard J. Ablin
      affiliation:
            name:Innapharma Inc., 10 Mountainview Road, Suite 301, Upper Saddle River, NJ 07458-1935, USA Tel.: +1(201) 818 1160 Fax: +1(201) 818 3388
            address:
               name:Innapharma Inc., 10 Mountainview Road, Suite 301, Upper Saddle River, NJ 07458-1935, USA Tel.: +1(201) 818 1160 Fax: +1(201) 818 3388, , US
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Innapharma Inc., 10 Mountainview Road, Suite 301, Upper Saddle River, NJ 07458-1935, USA Tel.: +1(201) 818 1160 Fax: +1(201) 818 3388, , US
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(25)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.41s.

LINK . SPRINGER . COM {}